With respect to breast cancer development, rhythmic clock gene expression is suppressed or obliterated in more aggressive cancer types, whereas a functional circadian clock is often retained in ER+, human epidermal growth factor receptor 2-negative (HER2-), low-grade breast cancers that have not yet metastasized [51]. This evidence concerns the gene ERBB2 and cancer.